Related Experiment Videos
The Tromsø Heart Study: serum apolipoprotein AI concentration in relation to future coronary heart disease
Insights
Lower apolipoprotein AI concentrations in high-density lipoprotein (HDL) were observed in individuals who later experienced coronary events. This finding suggests apolipoprotein AI may be a useful biomarker for predicting heart disease risk.
Area of Science:
- Cardiovascular Medicine
- Biochemistry
- Lipid Metabolism
Background:
- High-density lipoprotein (HDL) plays a crucial role in reverse cholesterol transport.
- Apolipoprotein AI (apoAI) is the primary structural and functional peptide of HDL.
- Dysregulation of HDL and apoAI is implicated in cardiovascular disease pathogenesis.
Purpose of the Study:
- To investigate the association between serum apolipoprotein AI concentrations and the incidence of coronary events.
- To compare apolipoprotein AI levels in individuals who experienced coronary events with matched controls.
- To evaluate apolipoprotein AI as a predictor of coronary heart disease.
Main Methods:
- Serum samples were collected from subjects who developed coronary events and matched controls.
- Apolipoprotein AI concentrations were measured using immunoelectrophoresis.
- Serum total cholesterol, triglyceride, and HDL cholesterol levels were also assessed.
- Discriminant function analysis was employed to assess predictive power.
Main Results:
- Mean apolipoprotein AI concentration was significantly lower in cases compared to controls, independent of total cholesterol and triglycerides.
- No significant difference was found in the HDL cholesterol to apolipoprotein AI ratio between cases and controls.
- Apolipoprotein AI concentration was a less potent predictor of coronary heart disease than HDL cholesterol.
Conclusions:
- Reduced serum apolipoprotein AI levels are associated with an increased risk of future coronary events.
- While apoAI is lower in those with events, HDL cholesterol remains a stronger predictor of coronary heart disease.
- These findings highlight the complex role of HDL composition in cardiovascular risk assessment.
Abstract:
The concentrations of apolipoprotein AI, a major peptide of high density lipoprotein (HDL), have been measured by immunoelectrophoresis in samples of serum from twelve subjects who subsequently developed a coronary event during 2 years of follow-up and compared with those in serum from sixteen matched control subjects. The mean apolipoprotein AI concentration in the cases was significantly lower than that in the controls, independently of the serum total cholesterol and triglyceride concentrations. There was no significant difference between the cases and controls in mean HDL cholesterol: apolipoprotein AI ratio. Within several case-control pairs, however, the difference in apolipoprotein AI concentration was proportionately much less than that in HDL cholesterol. On discriminant function analysis, apolipoprotein AI concentration was a less powerful predictor of coronary heart disease than was HDL cholesterol.